Varsha G. Desai
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Research Biologist
Also affiliated: United States Food and Drug Administration (2004–2023); King Edward Memorial Hospital and Seth G.S. Medical College (1991); Thomas Jefferson National Accelerator Facility (2001); University of California San Diego (2011); MIT World Peace University (2025–2026); Genomics (United Kingdom) (2004)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Varsha G. Desai's research focuses on understanding the mechanisms of drug-induced toxicity, particularly cardiotoxicity associated with the chemotherapy agent doxorubicin. Her work investigates how this drug affects the heart, with a recent emphasis on identifying early preclinical biomarkers for chronic cardiotoxicity. Desai has published studies exploring the role of microRNAs, such as microRNA-34a-5p, as potential circulating biomarkers for detecting this condition before clinical symptoms manifest.
Her research also examines sex-related differences in doxorubicin-induced cardiotoxicity, investigating pathways like the apelin-APJ system. Desai has explored strategies to mitigate this toxicity, including targeting the apelin-APJ axis. Her work has involved studies in animal models, including mice and rats, to elucidate disease mechanisms and evaluate potential therapeutic interventions. Collaborations include researchers from the National Center for Toxicological Research and the University of Arkansas for Medical Sciences.
Metrics
- h-index: 25
- Publications: 69
- Citations: 1,955
Selected Publications
-
Correction: Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study (2026)
-
Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study (2025)
-
Doxorubicin Cardiotoxicity: Preclinical and Clinical Circulating Protein Markers (2023)
-
Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice (2022)
-
Doxorubicin Cardiotoxicity: Preclinical and Clinical Circulating Protein Markers (2022)
-
MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity (2022)
-
Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice (2021)
-
Rebuttal to the comments by Dr. Yan Xu on the article “Transcript profiling in the testes and prostates of postnatal day 30 Sprague-Dawley rats exposed prenatally and lactationally to 2-hydroxy-4-methoxybenzophenone” (2019)
-
Candidate early predictive plasma protein markers of doxorubicin-induced chronic cardiotoxicity in B6C3F1 mice (2018)
-
Transcript profiling in the testes and prostates of postnatal day 30 Sprague-Dawley rats exposed prenatally and lactationally to 2-hydroxy-4-methoxybenzophenone (2018)
-
In Vitro Modulation of Redox and Metabolism Interplay at the Brain Vascular Endothelium: Genomic and Proteomic Profiles of Sulforaphane Activity (2018)
-
MitoChip (2018)
-
Sex and age differences in the expression of liver microRNAs during the life span of F344 rats (2017)
-
Sex-related differential susceptibility to doxorubicin-induced cardiotoxicity in B6C3F1 mice (2016)
-
Early metabolomics changes in heart and plasma during chronic doxorubicin treatment in B6C3F<sub>1</sub> mice (2016)
Collaboration Network
Top Collaborators
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Correction: Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Correction: Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Doxorubicin Cardiotoxicity: Preclinical and Clinical Circulating Protein Markers
- Doxorubicin Cardiotoxicity: Preclinical and Clinical Circulating Protein Markers
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Correction: Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Correction: Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice
- Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice
Similar Researchers
Based on overlapping research topics